Business Description
Parabilis Medicines is a Cambridge, Massachusetts-based drug discovery company founded in 2015 that builds medicines using a special class of stabilized peptide molecules capable of reaching targets inside cells that most drugs cannot. The company's lead program, FOG-001, is currently in clinical trials as a cancer treatment that works by blocking a key protein involved in tumor growth. Parabilis also uses artificial intelligence to guide how it designs drugs and runs trials, and its broader pipeline spans several approaches to fighting cancer, including targeted protein degraders and radiopharmaceuticals.
